Journals / Solunum / 2015 / Cilt: 17 - Sayı: 3

Costs of the Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in a University Hospital

Journal
Solunum
Pages
171–175
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Acute exacerbation of COPD continues to be an important cause of mortality and economic burden in the hospitalized COPD patients in pulmonary clinics

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic obstructive pulmonary disease (COPD), although a preventable and treatable disease continues to be a major health problem.
📊
Key Findings & Data:Acute exacerbations of COPD is a major cause of hospitalization of patients and it constitutes a significant portion of COPD-related health care costs.
💡
Conclusion & Impact:Conclusion: Acute exacerbation of COPD continues to be an important cause of mortality and economic burden in the hospitalized COPD patients in pulmonary clinics
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Chronic obstructive pulmonary disease (COPD), although a preventable and treatable disease continues to be a major health problem. Acute exacerbations of COPD is a major cause of hospitalization of patients and it constitutes a significant portion of COPD-related health care costs. In this study, we aimed to determine the cost of patients hospitalized with acute exacerbations of COPD in a university hospital. Methods: Data of the patients that were hospitalized due to COPD exacerbation between 1 September 2013-1 September 2014 in Hospital of Gazi University Medical Faculty were retrospectively analyzed. Cost data were gathered from data processing department. Costs were identified for drugs, laboratory tests, bed costs and other materials.Results: A total of 790 patients were hospitalized during twelve months. Among these patients 181 (23.0%) patients had COPD and 99 (12.5%) were hospitalized due to acute exacerbation of COPD. Of these 99 patients 77 (77.8%) were male and 22 (22.2%) were female. Forty-nine (49.5%) patients were hospitalized from the emergency department, 50 (50.5%) patients were from the outpatient clinic. The median age was 70 years old and median length of hospital stay was 8 days. Ninety-one (91.9%) of them were discharged from the service. Eight (8.1%) patients were transfered to the intensive care unit (ICU) due to respiratory failure, and 7 of these patients (7.4%) hospitalized back to the service after treatment at ICU, 2 (2.1%) patients died. The median cost per patient was 1.064 (726-1.866) Turkish Lira (TL). Drug costs accounted the largest portion (36.0%) of the median cost, followed by bed cost (26.0%). Two (2.1%) of patients died in hospital. Although the number of patients without antibiotic usage is less (17.2% vs 82.8%); the median cost per patient in the antibiotic using group was higher than that were without antibiotic using (median 643 vs 1.162 TL p=0.001). Presence of a comorbidity, hypoxemia, noninvasive mechanical ventilation (NIMV) requirement were existing factors that didn't increase the cost of patients (p>0.05). Only the use of antibiotics was detected as independent factors that increase the total cost (95% CI 0.487 to 12.984, p=0.030). Conclusion: Acute exacerbation of COPD continues to be an important cause of mortality and economic burden in the hospitalized COPD patients in pulmonary clinics

🔖

Cite This Article

YILDIRIM, F., TÜRK, M., ÖZTÜRK, C. (2015). Costs of the Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in a University Hospital. Solunum, Cilt: 17 - Sayı: 3, 171–175. https://ajindex.com/articles/314269

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2012
  2. Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda: Natio- nal Institutes of Health; 2012. Wouters EF. Economic analysis of the Confronting COPD survey: an over- view of results. Respir Med 2003; 97: 3-14. [CrossRef] Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position pa- per. Eur Respir J 2004; 23: 932-46. [CrossRef] Dalal AA, Shah M, D'Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011; 105: 454-60. [CrossRef] Örnek T. Zonguldak il merkezinde kronik obstrüktif akciğer hastalığı preva- lansının değerlendirilmesi. Uzmanlık Tezi. Zonguldak 2006.
  3. Kocabaş A, Hancıoğlu A, Türkyılmaz S, Ünalan T, Umut S, Çakır B, et al. Pre- valence of COPD in Adana, Turkey (BOLD-Turkey Study). Proceedings of the American Thoracic Society 2006; 3 (Abstract Issue): A543. T.C. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü Türkiye Kro- nik Hava Yolu Hastalıklarını (Astım - KOAH) Önleme Ve Kontrol Programı (2009 - 2013) Eylem Planı. http://www.saglik.gov.tr/TR/ dosya/1-73897/h/ turkiye-khh-astim-koah-onleme-ve-kontrol-programi-2009.
  4. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http:// www.goldcopd.org. Mathers CD, Loncar D. Projections of global mortality and burden of dise- ase from 2002 to 2030. PLoS Med 2006; 3: e442. [CrossRef] Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obst- ruct Pulmon Dis 2012; 7: 183-99. [CrossRef] Nielsen R, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, Gulsvik A, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009; 34: 850-7. [CrossRef] Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Na- varro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-31. [CrossRef] Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic im- pact of exacerbations of chronic obstructive pulmonary disease and exa- cerbation definition: a review. COPD 2010; 7: 214-28. [CrossRef] Perera PN, Armstrong EP, Sher